Vitamin K2

Vitamin K1 (phylloquinone) and vitamin K2 (menaquinones) are both fat-soluble vitamins with similar molecular structures but importantly different tissue distribution and half-life profiles. K1 is abundant in leafy green vegetables (spinach, kale, collards) and is taken up preferentially by the liver, where it supports coagulation factor carboxylation. K1 has a short plasma half-life (1-2 hours) and reaches extrahepatic tissues (bone, arterial wall) less reliably. K2 comes primarily from fermented foods (natto especially) and animal products (hard cheeses, egg yolks, grass-fed dairy/meat); the long-chain form MK-7 has a 72-hour plasma half-life and distributes effectively to bone and arterial tissue via lipoprotein particles. The practical implication is that K2 supplementation is preferred over K1 for targeting extrahepatic vitamin K-dependent proteins—osteocalcin (bone) and MGP (arterial wall)—which matter for bone mineralization and prevention of vascular calcification. Both forms support coagulation equally well; the differences emerge in extrahepatic tissue function.

For most adults taking a daily supplement, MK-7 is the simpler and more evidence-based choice: 100-200 mcg once daily provides sustained 24-hour vitamin K activity due to MK-7's 72-hour half-life, and the Knapen 3-year bone trial at 180 mcg (PMID 23525894) is the most robust nutritional-dose RCT. MK-4 has a very short half-life (1-3 hours), which means a single daily dose provides only a few hours of effective activity; MK-4 dosing makes sense either at pharmacologic levels (15 mg TID = 45 mg/day total, as used in Japanese osteoporosis therapy per Shiraki PMID 11007146) or in divided 2-3x daily low doses. Some users combine MK-7 (for steady baseline activity) with a lower dose of MK-4 (for pulsed peak activity), which is mechanistically reasonable but not clearly superior to MK-7 alone in clinical trials. For simplicity and consistency: MK-7 100-200 mcg daily with a fat-containing meal is the default recommendation.

It is strongly recommended. Vitamin D increases calcium absorption and upregulates osteocalcin production in osteoblasts. Without K2, the newly-produced osteocalcin remains undercarboxylated and cannot properly direct calcium to bone, while matrix Gla protein (MGP) in vascular smooth muscle cells remains undercarboxylated and cannot prevent calcium deposition in arterial walls. The theoretical concern—raised by Masterjohn's 2007 review and later research—is that high-dose D3 without K2 may worsen arterial calcification in susceptible individuals. While the clinical magnitude of this concern at typical D3 doses (2,000-4,000 IU) is debated, the mechanistic logic is sound, the cost of adding K2 is trivial ($8-15/month), and the expected benefit to bone and arterial health is real. Practical recommendation: anyone taking vitamin D3 1,000 IU or more daily should also take MK-7 100-200 mcg daily. Many quality combination products deliver D3 + K2 in a single capsule for convenience. See /compound/vitamin-d for the complete vitamin D picture.

Possibly, if your diet is deliberately K2-rich. The single best food source is natto (fermented soybeans) at 400-1,000 mcg MK-7 per 100 g serving; 2-3 portions weekly can substantially meet K2 needs. Hard aged cheeses (Gouda, Edam, Brie, Jarlsberg) provide 15-30 mcg MK-8/MK-9 per 30 g serving; several weekly servings contribute meaningfully. Pasture-raised egg yolks, grass-fed butter, organ meats, and fermented vegetables (kimchi, sauerkraut) add smaller amounts. However, typical Western diets deliver only 20-40 mcg K2 daily—well below the levels associated with cardiovascular and bone benefits in observational studies (>32 mcg/day in the Rotterdam cohort, Geleijnse PMID 15514282). Those unwilling or unable to incorporate natto or substantial hard-cheese consumption are better served by a daily MK-7 supplement at 100-200 mcg. For most Western users, supplementation is simpler and more consistent than dietary optimization alone.

It requires careful management with warfarin and similar vitamin K antagonists (acenocoumarol, phenprocoumon) but is generally safe with direct oral anticoagulants (DOACs) and antiplatelet drugs. Warfarin works by depleting reduced vitamin K to prevent coagulation factor carboxylation. Adding K2 opposes this effect and can lower INR, risking thrombosis. Do NOT start or stop K2 while on warfarin without coordination with your anticoagulation clinic. If K2 supplementation is clinically indicated (e.g., osteoporosis), your warfarin dose can be titrated upward to maintain target INR while on consistent K2. The key is consistency: stable daily K2 dose allows stable warfarin dosing. For DOACs (apixaban, rivaroxaban, edoxaban, dabigatran), there is no interaction—K2 is safe without dose adjustment. For aspirin, clopidogrel, and other antiplatelets, K2 is also safe. If you are on warfarin and interested in K2, discuss with your cardiologist, hematologist, or anticoagulation clinic.

For general foundational supplementation in most adults, MK-7 100-200 mcg daily with a fat-containing meal is the standard dose. This range normalizes extrahepatic vitamin K biomarkers (ucOC, dp-ucMGP) over 4-8 weeks and was the dose used in the Knapen 3-year postmenopausal bone trial (180 mcg, PMID 23525894). If you are taking higher-dose vitamin D (5,000 IU or more), consider scaling MK-7 to 200 mcg. For osteoporosis therapeutic intent under clinician guidance, MK-4 at 45 mg/day split TID (Japanese protocol, Shiraki PMID 11007146) has dedicated evidence for fracture reduction. For higher-dose investigational protocols (CKD, severe vascular calcification), 360-720 mcg MK-7 daily has been studied but should be coordinated with a clinician. Essentially nobody needs more than 1 mg/day for non-warfarin-reversal purposes. There is no established upper limit for K2 based on toxicity data; doses have been tested up to several mg daily without adverse effects in non-anticoagulated individuals.

In individuals not taking vitamin K antagonists, no. K2 at standard supplement doses (100-200 mcg MK-7 or even 15-45 mg MK-4) does not produce hypercoagulability, does not cause thrombosis, and does not shorten bleeding time in healthy adults. The liver's coagulation factor carboxylation is typically already saturated at lower vitamin K intakes; adding more K2 does not drive further coagulation factor activation. Population studies of individuals with high dietary K2 intake (Japanese natto consumers, Dutch high-K2 quartiles) show reduced cardiovascular mortality, not increased thrombosis. The only population in which K intake meaningfully affects coagulation is warfarin users (see prior question). For everyone else, K2 is not a 'blood thickener' in any clinically meaningful sense, and standard lab tests (PT, PTT, INR) remain in normal ranges with K2 supplementation.

Current evidence suggests K2 can slow progression of arterial calcification and improve functional arterial health markers, but does not reliably reverse established calcification. The Knapen 2015 RCT (PMID 25694037) showed MK-7 180 mcg/day for 3 years significantly improved carotid-femoral pulse wave velocity (arterial stiffness) in postmenopausal women, with greater effect in those with higher baseline stiffness. The Rotterdam Study observationally associated higher K2 intake with less severe aortic calcification. However, trials specifically demonstrating regression of coronary artery calcium (CAC) with K2 are lacking—CAC typically progresses over time even with optimal therapy, and the realistic goal of K2 is slower progression, not regression. If you have a high CAC score, K2 is a sensible addition to a comprehensive cardiovascular-risk-reduction stack (statin as indicated, BP control, diabetes management, omega-3, exercise, dietary optimization), not a standalone reversal agent. Expect biomarker changes (dp-ucMGP, pulse wave velocity) within months; morphological calcification changes are slow and incomplete.

Yes, though the most useful tests are not routine. The standard coagulation tests (PT, PTT, INR) are insensitive to extrahepatic K status—they only abnormalize with severe, clinically significant hepatic K deficiency. More useful markers for peripheral K status: undercarboxylated osteocalcin (ucOC), often reported as ucOC/total OC ratio—sensitive to bone K status; and dephospho-uncarboxylated MGP (dp-ucMGP)—sensitive to vascular K status and associated with cardiovascular events in multiple cohorts. Both biomarkers are available at specialty labs (not routine chemistry panels). In the absence of testing, the prior probability of subclinical K2 inadequacy in Western populations is high enough that empirical supplementation at 100-200 mcg MK-7 daily is low-risk and reasonable for most adults. Testing is most useful if pursuing clinically-specific goals (documented osteoporosis, established vascular calcification, CKD) where dose titration and confirmation of target engagement matter.

In non-warfarin patients, long-term K2 supplementation at typical doses has an excellent safety profile. No clinical toxicity syndrome has been identified for K2 at doses up to several mg daily in clinical trials or post-market experience. No tolerable upper limit has been established by the Institute of Medicine or European Food Safety Authority. The biological reason for this wide safety margin is that K2's sole biochemical role—acting as a cofactor for gamma-glutamyl carboxylase—is self-limited once all target substrate proteins are carboxylated; excess K does not drive additional downstream toxicity. Reported adverse effects are rare and mild: occasional GI upset, rare allergic reactions to capsule excipients. There are no documented effects on liver, kidney, bone, cardiovascular (positive rather than negative), or neurological function from long-term K2 supplementation. The only meaningful long-term concern is the anticoagulation interaction (warfarin and related drugs)—which is manageable with clinical coordination—and the broader advisory to coordinate with healthcare providers when adding any supplement to a complex medication regimen. For healthy adults, 100-200 mcg MK-7 daily can reasonably be taken indefinitely without concern.